CytomX: CytomX to Cut 40% of Staff as It Updates Pipeline Priorities

CytomX's workforce cuts could leave the biotech with fewer than 75 employees as it focuses resources on its wholly owned clinical-stage programs, most notably an antibody-drug conjugate for advanced metastatic colorectal cancer.